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Introduction: Cisplatin and docetaxel (Doc) are commonly used for
adjuvant therapy for non-small cell lung cancer based on extrapo-
lation from the metastatic setting. Nevertheless, essentially no data
have been published on this regimen in the adjuvant context, leading
to controversy, particularly surrounding feasibility.
Methods: Using a tumor database augmented with chart reviews,
we retrospectively evaluated treatment outcomes of all patients
receiving postoperative cisplatin (75 mg/m2) and Doc (75 mg/m2)
between August 2003 and November 2008. During this period, this
regimen was considered to be the first choice regimen for suffi-
ciently fit patients at the University of Pennsylvania
Results: The database captured 54 patients. Overall, 85.2% received
all four planned cycles (83.3% at full dose). Chart review allowed
definitive assessment of toxicity in 47 patients. A single patient (2%)
died of grade 5 febrile neutropenia. There was no grade 4 toxicity,
and 8.5% experienced grade 3 febrile neutropenia. No febrile neu-
tropenia was observed in 26 patients given prophylactic peg-filgras-
tim. The incidence was 23.8% in the 21 patients not given peg-
filgrastim during the first cycle; 6.4% each experienced grade 3
gastritis, anorexia, nausea, and fatigue, and 2.1% experienced grade
3 diarrhea. Median progression-free survival was 17.9 months, and
median overall survival has not been reached.
Conclusion: Cisplatin and Doc are feasible in the adjuvant setting
with superior dose delivery and convenience compared with historic
data with cisplatin and vinorelbine.
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Lung cancer is the leading cause of cancer-related death inthe United States. Less than half of patients undergoing
definitive surgical resection for early-stage non-small cell
lung cancer (NSCLC) are cured of their disease.1,2 Chemo-
therapy has been used in an attempt to improve outcomes.
Treatment with cisplatin-containing doublets resulted in a
5.4% absolute survival benefit at 5 years in the Lung Adju-
vant Cisplatin Evaluation (LACE) meta-analysis.3 Two of the
trials included in this meta-analysis, ANITA4 and JBR.10,5
used only cisplatin (CDDP) and vinorelbine (vin); and in the
largest trial to date, International Adjuvant Lung Trial
(IALT), more than 25% of patients enrolled onto the chemo-
therapy arm received this regimen. Forest plots in LACE
showed a greater survival advantage in these two CDDP-vin
containing trials than for any other regimens in the analysis.
Further, when subgroups were analyzed in LACE, CDDP-vin
adjuvant therapy provided a larger survival advantage com-
pared with other CDDP doublets. Thus, CDDP-vin has set the
standard of care for adjuvant therapy and, to date, remains the
most widely investigated chemotherapy combination in the
modern adjuvant era.
Docetaxel (Doc)-containing regimens were not studied in
any of the trials comprising LACE. Nevertheless, the TAX3266
study demonstrated trends toward improved response rate
(p.029), overall survival (OS, p.044), and quality of life (p.064
for lung cancer symptom scale and p.016 for EuroQol) for
CDDP-Doc compared with CDDP-vin in the metastatic setting.
This trial prompted many thoracic oncologists to hypothesize
that the CDDP-Doc doublet might be superior in the adjuvant
setting, and this regimen has been included as one of four
featured in the ongoing phase III intergroup trial, E1505, com-
paring cisplatin-based chemotherapy versus chemotherapy plus
bevacizumab. Others have argued that extrapolation from the
metastatic setting is a flawed assumption and that dose delivery
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of CDDP-Doc is not feasible because of toxicity, particularly
myelosuppression, in the postoperative period.
At the Hospital of the University of Pennsylvania, CDDP-
Doc was adopted as the standard adjuvant regimen after TAX-
326. Therefore, we set out to capture all patients treated at our
institution in the adjuvant setting using this regimen.
METHODS
Database
Information was prospectively entered into the pass-
word-protected tumor database, which was maintained on
Microsoft Access. Data were extracted for all patients treated
with curative-intent surgery followed by at least one cycle of
CDDP-Doc at the University of Pennsylvania. Data for base-
line characteristics, histology, treatment, progression, and
survival were all collected prospectively, entered into the
database, and extracted from it for this analysis. Toxicity data
were obtained retrospectively by chart review and graded by
CTCAE version four. When available, social security death
index was used to augment survival data in patients lost to
follow-up.
Data Extraction
Toxicity data were extracted retrospectively by chart
review. To be considered evaluable for toxicity, a complete
review of systems with specific commentary on presence or
absence of symptoms, and their severity was required. When
chart records were ambiguous as to the grade of toxicity, we
defaulted to the higher grade.
Treatment data were extracted from order sheets. These
sheets were signed by the practitioner and verified by a
pharmacist; in addition, it should be noted that two nurses
independently signed the orders to confirm that the written
therapy was actually administered.
Treatment
Between August 2003 and November 2008, CDDP-
Doc was considered the first choice regimen for eligible
patients. Patients were treated with CDDP 75 mg/m2 and doc
75 mg/m2 on day 1 of a 21-day regimen. Patients were given
1 liter of normal saline before and 500 ml after cisplatin; as
needed, home intravenous fluid (IVF) was administered.
Patients were given individualized antiemetic regimens rou-
tinely using 5HT3 inhibitors; aprepitant was used when
available. Pegylated filgrastim was used as needed and in
some patients, as prophylaxis during the first cycle.
Statistical Analysis
Data queried from Microsoft Access were exported into
Microsoft Excel where all calculations were performed. The
primary study end point was feasibility, as measured by
number of cycles administered. Prespecified secondary end
points included toxicity, dose reductions, OS, and median
survival. OS and progression-free survival (PFS) were plotted
by the standard Kaplan method. Median actual overall and
PFS were arithmetically calculated in Microsoft Excel.
RESULTS
Demographic Data
Our tumor database captured 54 patients treated be-
tween August 2003 and November 2008 with this regimen
after curative-intent surgery. Demographic data are shown in
Table 1. Overall, 46.3% of patients were female. African
American patients represented 14.8% of the population. One
patient had PS2, and another patient had PS3; 18.5% had
PS0, and the remaining 77.8% of patients had PS1. 61.1% of
patients had stage I or II NSCLC; 25.9% had stage IIIa
NSCLC, 11.1% had stage IIIb disease, and a single patient
(1.9%) had stage IV NSCLC. All patients with IIIB disease
qualified for this designation on the basis of T4 involvement
and not N3 disease. One patient had disease invading the
main pulmonary vein, and five had satellite nodules; 63% of
patients had adenocarcinoma, and 20.4% squamous cell car-
cinoma.
TABLE 1. Baseline Characteristics (n  54)
Median age (range) 58.5 (34–74)
Sex
Male 29 (53.7)
Female 25 (46.3)
Race
Caucasian 41 (75.9)
African American 8 (14.8)
Other 6 (9.3)
ECOG performance status
0 10 (18.5)
1 42 (77.8)
2 1 (1.9)
3 1 (1.9)
Stage
I 14 (25.9)
II 19 (35.2)
IIIa 14 (25.9)
IIIb 6 (11.1)
IV (isolated brain) 1 (1.9)
Tumor histology
Adenocarcinoma 34 (63)
Squamous cell carcinoma 11 (20.4)
Large cell carcinoma 4 (7.4)
BAC or adenocarcinoma with BAC features 3 (5.6)
NSCLC, NOS 2 (3.7)
Smoking status (for 45 patients with data available)
Any history of smoking 35 (79.6)
Never smoker 9 (20.4)
Surgery type
Lobectomy 42 (77.8)
Pneumonectomy 7 (13)
Other 5 (9.3)
Treated with adjuvant radiation therapy 9 (16.7)
Percentages are given in parentheses.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer;
NOS, not otherwise specified.
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Dose Delivery
Overall, 85.2% of patients received all four planned
cycles of CDDP-Doc, 5.6% received 3 cycles, 1.9% received
2 cycles, and 7.4% received one cycle. Two patients required
dose reduction, one of whom received all four cycles of
therapy. Hence, 83.3% of the overall cohort were treated with
four cycles at full dose. Two of the four patients receiving a
single cycle of CDDP-doc subsequently received three addi-
tional cycles of carboplatin-doc.
The minimum interval from surgery to chemotherapy
was 3.7 weeks, the maximum was 21.9 weeks, and the
median was 8 weeks. Overall, 90.7% of patients were treated
within 8 weeks. Of patients receiving four cycles, the median
duration of chemotherapy was 8.9 weeks, with a minimum
duration of 8.6 weeks and a maximum duration of 11.7
weeks. All patients completed chemotherapy within 12
weeks.
Radiation Therapy
Seven patients were treated with adjuvant radiation
therapy after chemotherapy, at a median interval of 10.4
weeks with a minimum interval of 8.6 weeks and a maximal
interval of 15.9 weeks. The mediastinum of each of these
patients harbored disease, and two also had positive margins.
A single patient was treated before chemotherapy, at an
interval of 7.9 weeks after surgery, with chemotherapy 8.6
weeks later; this patient had a positive surgical margin but no
mediastinal disease.
Toxicity
CDDP-Doc toxicity is summarized in Table 2. The
most frequent grade  3 toxicity was febrile neutropenia.
Overall, 8.5% of the 47 patients for whom toxicity data were
available experienced febrile neutropenia. Of these 47 pa-
tients, 26 received up-front peg-filgrastim; none of these
patients experienced this complication. Twenty-one patients
did not receive peg-filgrastim and five, or 23.8% of these,
sustained febrile neutropenia. Of these 5 patients, one died of
febrile neutropenia. In seven patients, the use or lack of use of
peg-filgrastim could not be confirmed from chart records.
Additional grade 3 side effects included fatigue, nausea,
and gastritis, affecting 6.4% of the patients each and
diarrhea affecting 2.1%; there were no grade 4 toxicities.
Of 29 patients who received up-front aprepitant, 86.2%
experienced any grade nausea, and 34.5% experienced
grade 2 or 3 nausea. Of 18 patients who did not receive
up-front aprepitant, 83.3% experienced any grade nausea,
and 22.2% experienced grade 3 nausea. Full toxicity data
are shown in Table 2.
Outcomes
OS and PFS are shown in Figures 1 and 2. Overall
median survival has not yet been reached, with actual 1-year
survival of 85.2% and actual 2-year survival of 68.1% for
patients with at least 2 years of follow-up. Median PFS was
reached at 17.9 months, with 1 year actual PFS of 67.3% for
patients with at least a year of follow-up for progression and
2 year PFS of 50% for those with at least 2 years of potential
follow-up. Of note, follow-up for many surviving patients
FIGURE 1. Overall survival. Num-
ber at risk (NAR).
TABLE 2. Toxicity of Therapy (%)
Grade
0
Grade
1
Grade
2
Grade
3
Grade
4
Grade
5
Fatigue 27.7 51.1 14.9 6.4 0.0 0.0
Nausea 14.9 55.3 23.4 6.4 0.0 0.0
Diarrhea 63.8 27.7 6.4 2.1 0.0 0.0
Anemia 66.0 27.7 6.4 0.0 0.0 0.0
Anorexia 68.1 12.8 12.8 6.4 0.0 0.0
Emesis 78.7 12.8 8.5 0.0 0.0 0.0
Neuropathy 80.9 17.0 2.1 0.0 0.0 0.0
Constipation 83.0 14.9 2.1 0.0 0.0 0.0
Myalgia 80.9 17.0 2.1 0.0 0.0 0.0
Febrile neutropenia 89.4 0.0 0.0 8.5 0.0 2.7
Gastritis 89.4 0.0 4.3 6.4 0.0 0.0
Edema 93.6 6.4 0.0 0.0 0.0 0.0
Tinnitus 93.6 6.4 0.0 0.0 0.0 0.0
Bone pain 95.7 2.1 2.1 0.0 0.0 0.0
Rash 97.9 2.1 0.0 0.0 0.0 0.0
Infusion reaction 97.9 0.0 2.1 0.0 0.0 0.0
The values are given in percentages.
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remains immature, creating divergence between actual out-
comes and those estimated by Kaplan-Meier plots. Censoring
is quantified by annotation of OS and PFS curves with
number at risk.
In accordance with prespecified criteria, all patients
treated with adjuvant CDDP-Doc were included in the anal-
ysis. Included in these results are seven patients who would
not have been candidates for the formal adjuvant trials. Six
patients had stage IIIb disease by virtue of T4 primary, and a
single patient each had an isolated brain metastasis, two
synchronous stage Ia primaries, PS2, and PS3. When these
patients are excluded, 44 patients remain. In this population,
88.6% received four full cycles. For this population, median
OS has not been reached, and mPFS is 15.4 months. Actual
1-year OS is 84.1%, and for those with at least 2 years
elapsed since resection, 78.0% remain alive. For those with
at least a year elapsed since resection, PFS is 79.5%, and
for those with at least 2 years of follow-up data for
progression, 50.0%.
DISCUSSION
To the best of our knowledge, this report represents the
largest published study of the adjuvant treatment of NSCLC
with cisplatin and Doc. Treatment was feasible, with 83.3%
of patients receiving four full cycles of therapy and efficacy
at least comparable with the large adjuvant studies of CDDP-
vin. The study was neither prospective nor randomized.
Rather, patients were selected for treatment for CDDP-doc
based on the judgment of the treating physician and the
willingness of the patient. This selection strategy is consistent
with real-world, off-protocol, clinical decision making. The
consequence of this is reflected in the demographic data—
women, African Americans, and patients with T4 disease
by satellite nodules are represented as are a patient with
PS2, a patient with PS3, and a patient with two small
primary tumors.
Cisplatin-containing doublets demonstrated a 5.4% ab-
solute survival benefit in the LACE meta-analysis.3 The
CDDP-vin combination yielded a higher survival benefit than
other regimens, especially second generation regimens with
vinca alkaloids and etoposide and those featuring mitomycin.
The authors speculated that this difference may be due not to
superiority of vin but rather to increased dose-delivery of
cisplatin. Although cisplatin dose delivery may have been
higher when combined with vin than with other regimens,
dose delivery remained suboptimal. For example, only half of
patients assigned to chemotherapy on the ANITA trial re-
ceived all four cycles; and the median number of cycles
delivered in JBR.10 was three. In contrast, 83.3% of patients
in this series received four full doses. The importance of drug
delivery has been accepted by many oncologists and has been
well demonstrated in the adjuvant treatment of breast cancer.7
The TAX326 study in advanced incurable NSCLC
demonstrated higher dose delivery with CDDP-doc than with
CDDP-vin at a median of five cycles with CDDP-Doc, when
compared with a median of four cycles with CDDP-vin. This
difference in dose delivery may partially explain the differ-
ence in efficacy reported in this trial. Patients treated with
CDDP-doc lived a median of 11.3 months, compared with
10.1 months for CDDP-Vin (p  0.044). Response rate was
also higher for CDDP-doc at 31.6% compared with 24.5% for
CDDP-Vin (p  0.029).6 CDDP-Doc was also tolerable and
efficacious in the Swiss Group for Clinical Cancer Research
neo-adjuvant phase II study of stage IIIa patients.8 In this
study, 96% of patients received at least three cycles, the
response rate was 66% and median survival 33 months. In
contrast, a small phase II study from Memorial Sloan Ket-
tering Cancer Center (MSKCC) found CDDP-doc to be
poorly tolerated in the adjuvant setting both in a cohort given
weekly Doc and in another cohort given every 3-week Doc.9
Six of eleven patients were unable to complete three cycles in
the every 3-week cohort. For some oncologists, this report
engendered the notion that the CDDP-doc regimen is too
toxic in the adjuvant setting.
We chose to query the lung cancer database of the
Hospital of the University of Pennsylvania in response to
both this controversy and the inclusion of this regimen in the
ongoing Eastern Cooperative Oncology Group (ECOG)1505
trial. To date, the distribution of regimens used in E1505 has
not been reported; in addition to “standard” CDDP-vin,
enrollees may receive CDDP-doc, as well as CDDP-gemcit-
abine and CDDP-pemetrexed.
FIGURE 2. Progression-free sur-
vival. Number at risk (NAR).
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The population reported in our series contains a rela-
tively high proportion with advanced disease and has an
overall worse PS than the trials described in Table 3. All six
patients with stage IIIb disease qualified for this designation
through T4 stage and not N3 stage. As such, we considered
them appropriate for curative-intention surgery. Indeed, the
seventh edition of the TNM staging system will reclassify
these patients at T3 and thus stage IIB-IIIA, reflecting the
potential for cure. Similarly, we consider the patient with a
solitary metastasis potentially curable. Finally, some may
assume that the prognosis of these patients and those with
PS2–3 or multiple primary cancers would be expected to be
worse than patients with earlier-stage disease. This assump-
tion did not bear out in our analysis—when these 10 patients
were excluded, 88.6% of the remaining patients received four
full cycles of therapy with similar survival and freedom from
progression. We note that these patients were not randomized
but rather selected by the treating physicians at a weekly
multidisciplinary thoracic tumor board. We believe that per-
sonalized therapy through multidisciplinary collaboration
was key to achieving these results and strongly endorse the
practice.
In addition to dose-delivery, patient convenience is
increased with the CDDP-Doc regimen as compared with
CDDP-Vin, since treatment is administered every 3 weeks,
rather than on days 1 and 8 as in ANITA or weekly for 16
weeks as in JBR.10. Survival cannot be directly compared
with the major adjuvant trials but is within the expected
outcomes for this population. Feasibility and toxicity are
comparable with the CDDP-Doc arm of a randomized trial
presented at the World Lung Conference in 2009 comparing
adjuvant CDDP-Doc to CDDP-Gemcitabine.10
Although our database does not capture toxicity beyond
the surrogate measures of number of cycles delivered, we
were able to definitively evaluate toxicity from chart review
in 47 patients. In the MSKCC trial, severe fatigue was the
dose-limiting toxicity in four patients. Fatigue was the second
most common grade 3/4 toxicity in our series, affecting 6.4%
of patients. Aggressive maintenance of optimal volume status
with home intravenous fluids, if necessary, along with a
tapering dose of steroids following the recommended dexa-
methasone preparation have both been helpful in mitigating
this issue. One patient was limited by nausea in the MSKCC
study despite an aggressive and appropriate antiemetic regi-
men. Overall, 6.4% of our patients were also affected by
grade 3/4 nausea.
Finally, one of 11 patient in the Q3 week cohort of the
MSKCC trial developed fever and neutropenia. We routinely
used prophylactic pegylated filgrastim when feasible and
noted no febrile neutropenic events in the 26 of 47 (55.3%) of
patients who received primary prophylaxis with pegylated
filgrastim. In contrast, 23.8% of the 21 patients who did not
receive pegylated filgrastim experienced febrile neutropenia.
One of these patients died after initially refusing admission
for intravenous antibiotics. In the TAX326 study of CDDP-
doc in the metastatic setting, patients did not receive primary
prophylaxis but were permitted to receive secondary prophy-
laxis. Overall, 74.8% experienced grade 3/4 neutropenia,
defined as absolute neutrophil count  1000; however, only
4.8% experienced febrile neutropenia. A similar percentage
of patients (69%), on the CDDP-doc arm of ECOG 1594,11
experienced grade 3/4 neutropenia with 11% of the total
cohort experiencing febrile neutropenia. This 11% figure is
identical to the overall incidence in our analysis. ECOG and
National Comprehensive Cancer Network (NCCN) guide-
lines both recommend primary prophylaxis if the risk of
febrile neutropenia reaches 20%.12,13 As the rate of febrile
neutropenia in patients not treated with prophylactic pegy-
lated filastim reached 23.8% in our series, routine use of
primary prophylactic pegylated filgrastim would be consis-
tent with these recommendations.
CDDP-doc is not the right regimen for every adjuvant
patient. Our database captured 102 patients treated with at
least one cycle of adjuvant chemotherapy during the period
studied, with just over half receiving CDDP-Doc. Overall,
66.7% of the remaining 44 patients were treated with non-
cisplatin regimens with typical reasons including renal insuf-
ficiency, impaired hearing, preexisting neuropathy, and desire
to avoid nausea, and 52.1% chose treatment with gemcitabine
or pemetrexed, mostly from a preference to avoid alopecia.
Of note, some patients fit into both of these categories and
were thus treated with a noncisplatin, non-Doc regimen.
Treatment decisions incorporating the comorbid conditions
and expectations of the patient are an important part of
quality care.
The HUP series is relatively small and retrospective in
nature. Patients were selected for eligibility by the decision of
the treating physicians. Thus, advanced disease stage and
comorbidity are more substantial than in the major adjuvant
studies; however, alternative sources of selection bias may be
present. Toxicity data were retrospectively coded to CTCAE
v4. Although chart records were quite detailed, it is possible
TABLE 3. Select Relevant Adjuvant Trials in NSCLC
Trial Regimen Stage PS Cycles Delivered N mOS
ANITA CDDP: 100 mg/m2  4 and
Vin: 30 mg/m2  16
I: 36%, II: 22%, IIIa: 41%,
and IIIb–IV: 1%
WHO—0: 48%, 1: 47%, and
2: 3%
50% received four cycles 840 65.7 mo
JBR.10 CDDP: 50  2 mg/m2 and
Vin 25 mg/m2  16
Ib: 45% and II: 55% ECOG—0: 50% and 1: 50% Median of three cycles 242 94 mo
MSKCC CDDP: 75 mg/m2 and Doc:
80 mg/m2
IB: 18%, IIa: 18%, IIb:
37%, IIIa: 9%, and IIIb:
18%
Karnofsky 80%: 45% and
Karnofsky 90%: 55%
55% unable to complete
three cycles
11 Not reached at 18
mo follow-up
WHO, World Health Organization; ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer; MSKCC, Memorial Sloan Kettering Cancer Center.
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that minor toxicities were not recorded in the charts and that
the extent of toxicity may be under or over estimated retro-
spectively. Blood counts were not checked at nadir, resulting
in likely undercapture of cytopenias that did not result in
symptomatic toxicity. Finally, survival cannot be directly
compared with the major adjuvant trials because of different
methods of patient selection.
The ongoing ECOG1505 trial compares adjuvant chemo-
therapy with or without bevacizumab. The choice of CDDP
doublet is left to the discretion of the treating physician, with
choice of partner agents including vin, Doc, gemcitabine, and,
by recent amendment, pemetrexed. There are very little pub-
lished data on regimens other than vin and cisplatin in this
setting. Hence, our review, although relatively small, shows that
combination CDDP and Doc in this setting is safe and feasible;
and based on preliminary outcome data, it is likely to generate
similar efficacy to the vin-cisplatin regimen.
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